Who owns SMMT - Summit Therapeutics Inc. - COM based on 13F filings?

205 institutions reported positions in SMMT - Summit Therapeutics Inc. - COM as of Q4 2025. Open the latest holders period and ownership history tables on this page for position-level details.

Summit Therapeutics Inc. - COM (SMMT) Institutional Ownership

Q: What is CUSIP 86627T108?

CUSIP 86627T108 is the security identifier used in SEC filing datasets for SMMT - Summit Therapeutics Inc. - COM.

CUSIP: 86627T108

13F Institutional Holders and Ownership History from Q3 2020 to Q4 2025

Type / Class: Equity / COM
Symbol: SMMT on Nasdaq
Price per share: $15.68
All holders as of 31 Dec 2025: Q4 2025
Total 13F shares: 117,788,000
Total reported value: $2,060,259,947
% of total 13F portfolios: 0%
Share change: +14,928,945
Value change: +$249,329,721
Number of holders: 205
Price from insider filings: $15.68

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Investment Quick Answers

What is CUSIP 86627T108?
CUSIP 86627T108 identifies SMMT - Summit Therapeutics Inc. - COM in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Continue Investment Research

Latest 13F filings for new institutional portfolio disclosures.
Latest Schedule 13D/13G reports for activist and beneficial ownership updates.
Latest 10-Q/10-K reports to cross-check issuer fundamentals.
Recent insider transactions for management buying/selling context.
SEC investors directory and top value investors for manager-level discovery.
All institutional ownership pages to compare adjacent CUSIP pages.

Recent Quarterly Holder Reports

Open recent reporting periods for CUSIP 86627T108:

Q4 2025 (205 holders) Q3 2025 (230 holders) Q2 2025 (225 holders) Q1 2025 (199 holders) Q4 2024 (194 holders) Q3 2024 (164 holders) Q2 2024 (118 holders) Q1 2024 (102 holders) Q4 2023 (93 holders) Q3 2023 (91 holders)

As of 31 Dec 2025, 205 institutional investors reported holding 117,788,000 shares of Summit Therapeutics Inc. - COM (SMMT).

Institutional Holders of Summit Therapeutics Inc. - COM (SMMT) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (Median)	Investors
2025 Q4	117,788,000	$2,060,259,947	+$249,329,721	$65,876,085	$44,134,266	$17.49	205
2025 Q3	102,790,902	$2,124,233,076	+$101,213,528	$82,865,206	$97,512,172	$20.66	230
2025 Q2	97,848,320	$2,079,803,739	+$34,103,835	$66,962,488	$100,194,628	$21.28	225
2025 Q1	97,733,829	$1,887,229,142	+$89,016,064	$60,029,046	$35,579,905	$19.29	199
2024 Q4	92,613,844	$1,652,162,078	+$117,836,335	$45,320,095	$28,768,973	$17.84	194
2024 Q3	84,474,771	$1,848,145,011	+$298,396,085	$61,966,710	$43,380,016	$21.90	164
2024 Q2	72,164,786	$562,895,901	+$185,636,664	$7,915,120	$8,045,700	$7.80	118
2024 Q1	49,654,473	$205,842,486	+$72,450,894	$120,060	$426,006	$4.14	102
2023 Q4	32,347,368	$84,434,113	+$2,186,340	$18,270	$175,914	$2.61	93
2023 Q3	32,310,209	$60,420,216	-$5,139,413	$40,392	$1,098,064	$1.87	91
2023 Q2	34,903,696	$87,605,995	+$36,385,283	$60,491	$160,632	$2.51	96
2023 Q1	21,131,959	$36,976,249	+$21,762,761	$1,180,275	$1,292,200	$1.75	86
2022 Q4	8,101,933	$34,536,890	+$22,599,596	$3,516,400	$2,747,625	$4.25	57
2022 Q3	3,172,802	$3,773,379	-$5,112,229		$31,000	$1.19	37
2022 Q2	8,456,620	$8,456,000	-$4,226,540		$56,000	$1.00	33
2022 Q1	10,947,648	$26,824,000	-$299,864	$0	$32,000	$2.45	44
2021 Q4	11,033,765	$29,678,000	+$54,239	$42,000	$100,000	$2.69	49
2021 Q3	10,933,895	$54,779,617	-$944,411	$120,000	$437,000	$5.01	50
2021 Q2	11,040,017	$82,356,721	+$14,136,648	$229,000	$890,000	$7.46	52
2021 Q1	9,283,184	$54,489,348	+$1,359,001		$81,000	$5.87	36
2020 Q4	9,061,824	$42,589,259	+$2,512,909			$4.70	31
2020 Q3	7,749,222	$26,750,440	+$26,750,440			$3.44	15